TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04382547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Description: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study: NCT02824120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comedy
Description: patients will watch comedy film

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Documentary
Description: patients will watch a documentary film
Study: NCT00521105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual visit
Description: Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
Study: NCT04610190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Gait Enhancing and Motivating System (GEMS-H) Robot
Description: Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
Study: NCT05045391

Intervention type: DIAGNOSTIC_TEST
Intervention: Aspergillus IgG detection
Description: Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Aspergillus IgG detection
Description: Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
Study: NCT03507361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV-BASED MUSIC
Description: Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
Study: NCT02590744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye patch
Description: cover the sick eye with eye patch preoperatively for 3 hours

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: non-eye patch
Description: do not cover the sick eye with eye patch preoperatively
Study: NCT01699009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: an unrestricted diet
Study: NCT03514524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR imaging
Description: Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
Study: NCT03573973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved product placement of fresh fruit and vegetables
Description: The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
Study: NCT02720718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Study: NCT02763046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457) 150 mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457) 150 mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Secukinumab (AIN457) 150 mg s.c.
Description: Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
Study: NCT00840749

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Radiotherapy
Description: Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
Study: NCT00933907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 6 weeks
Study: NCT01071642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE/ARB stopped 24 hours before procedure and start immediately after
Description: ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
Study: NCT03079986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care irrespective of CL
Description: Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary treatment (MCT-diet)
Description: Dietary treatment with MCT-diet until resolution of CL.
Study: NCT04038463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFP
Description: This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LFP
Description: The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELP
Description: The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LLP
Description: The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
Study: NCT03926117

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziltivekimab
Description: human IgG1k anti-human IL-6 monoclonal antibody
Study: NCT06053346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pay For Performance (PFP)
Description: Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
Study: NCT02633293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
Study: NCT02595918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo metastasectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Undergo nephrectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03004274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running sutures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrupted sutures
Study: NCT02653963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunctival Triamcinolone
Description: Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
Study: NCT00794690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract for the group
Description: 40 mg of Cimicifuga racemosa extract daily dor 12 months
Study: NCT03898791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3295668 Erbumine
Description: oral capsules
Study: NCT00004919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04237376

Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 MG
Description: Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300 MG Oral Tablet
Description: Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
Study: NCT00483444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled telephone follow-up
Description: Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
Study: NCT03977467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab at a flat dose of 1200 mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: atezolizumab at a flat dose of 1200 mg IV every 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Arm A Only)
Description: Standard of care chemotherapy is defined as a platinum-doublet therapy (or triplet if bevacizumab is used) of the Investigator's choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: tiragolumab at a flat dose of 600 mg IV every 3 weeks
Study: NCT00828217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
Study: NCT00632268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001; Cisplatin; 5-FU; Leucovorin
Description: RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
Study: NCT04948346

Intervention type: OTHER
Intervention: diagnosed with ALS
Description: diagnosed with ALS
Study: NCT03655171

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-based quantitative methods
Description: The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
Study: NCT04588168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immediate Multiparametric MRI
Description: Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and Lymphadenectomy
Description: The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and Lymphadenectomy
Description: The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conventional Multiparametric MRI
Description: After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: conventional Multiparametric MRI
Description: After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Multiparametric MRI
Description: Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Baseline Multiparametric MRI
Description: Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
Study: NCT03760692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: Evaluation of clinical performance in terms of insertion, ventilation and complications
Study: NCT02717624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib in combination with BR
Study: NCT03760692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuroGain
Description: Evaluation of clinical performance in terms of insertion, ventilation and complications
Study: NCT02670226

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, muscle biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Samples
Description: Blood samples, muscle biopsy
Study: NCT01805063

Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber

Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber

Intervention type: PROCEDURE
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study: NCT03743051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: 100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo (administered as matching placebo tablets in the fasted condition)
Study: NCT02717624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib in combination with BR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib in combination with VR
Study: NCT04602520

Intervention type: BEHAVIORAL
Intervention: 3 Wishes Project
Description: Behavioral: Focused conversations at end-of-life to promote the connections between patients, family members, and clinicians.
Study: NCT03637998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving Pain to Enhance Living Well (PROPEL)
Description: PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
Study: NCT01190241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
Description: The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
Study: NCT02125058

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcutaneous sutures
Description: Conventional excision followed by subcutaneous sutrues and transcutaneous sutures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intracutaneous sutures
Description: Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
Study: NCT01614210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast cancer surgery
Description: Breast cancer surgery
Study: NCT03017508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-0223
Description: 35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.